[U] Returning To "Power Alley" Stuff... Pfizer Calls It Quits -- On Alzheimer's R&D

Updated @ 6 PM EST: Do watch the Meg Tirrell interview for more on this, toward the end of the segment. And catch Mr. Frazier’s glancing clap-back at 45 — about one and a half minutes in. . . Smile. End update.

I do know that Kenilworth's verubecestat program differs (and perhaps differs markedly) from the ones ever-squirrely Mr. Read was running -- but I think any sober person needs to carefully consider how many have fallen on their swords before them, here: Baxter, Lilly, Amgen, and now (larger than all of these put together). . . Pfizer.

The caution flags should be out, for Kenilworth. Bloomberg had it all, overnight:

. . . .The move to end the neuroscience-discovery program followed an internal review, the New York-based drugmaker said in an emailed statement. The job reductions will primarily affect employees at facilities in Cambridge and Andover in Massachusetts, as well as Groton, Connecticut. . . .

That's hundreds of millions of dollars. . . gone -- as well as 300 fine science jobs. Now you know. . . watching a chilly sunset -- in the steel canyons, jut beginning. . . be excellent to one another.

नमस्ते